Camicinal HCl

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 528604

CAS#: 923565-22-4 (HCl)

Description: Camicinal, also known as GSK-962040 and KB-77633, is an motilin receptor agonist potentially for the treatment of gastroparesis diabeticorum.

Price and Availability




Camicinal HCl is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to to inquire quote.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 528604
Name: Camicinal HCl
CAS#: 923565-22-4 (HCl)
Chemical Formula: C25H34ClFN4O
Exact Mass:
Molecular Weight: 461.0224
Elemental Analysis: C, 65.13; H, 7.43; Cl, 7.69; F, 4.12; N, 12.15; O, 3.47

Related CAS #: 923565-21-3 (free base)   923565-22-4 (HCl)    

Synonym: 962040, GSK-962040; KB-77633; GSK962040; KB77633; GSK 962040; KB 77633

IUPAC/Chemical Name: (S)-2-(4-((3-fluorophenyl)amino)piperidin-1-yl)-1-(4-((3-methylpiperazin-1-yl)methyl)phenyl)ethan-1-one hydrochloride


InChi Code: InChI=1S/C25H33FN4O.ClH/c1-19-16-30(14-11-27-19)17-20-5-7-21(8-6-20)25(31)18-29-12-9-23(10-13-29)28-24-4-2-3-22(26)15-24;/h2-8,15,19,23,27-28H,9-14,16-18H2,1H3;1H/t19-;/m0./s1


Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:


1: Hobson R, Farmer AD, Dewit OE, O'Donnell M, Hacquoil K, Robertson D, Barton ME, Dukes GE. The effects of camicinal, a novel motilin agonist, on gastro-esophageal function in healthy humans-a randomized placebo controlled trial. Neurogastroenterol Motil. 2015 Nov;27(11):1629-37. doi: 10.1111/nmo.12663. Epub 2015 Sep 8. PubMed PMID: 26348542.

2: Barshop K, Kuo B. The investigational drug camicinal for the treatment of gastroparesis. Expert Opin Investig Drugs. 2015 Jan;24(1):133-140. Epub 2014 Oct 24. PubMed PMID: 25341626.

3: Zala AV, Walker MM, Talley NJ. Emerging drugs for functional dyspepsia. Expert Opin Emerg Drugs. 2015 Jun;20(2):221-33. doi: 10.1517/14728214.2015.1009827. Epub 2015 Feb 3. Review. PubMed PMID: 25645940.

4: Peeters TL. Gastrointestinal hormones and gut motility. Curr Opin Endocrinol Diabetes Obes. 2015 Feb;22(1):9-13. doi: 10.1097/MED.0000000000000123. Review. PubMed PMID: 25517024.

5: Chapman MJ, Deane AM, O'Connor SL, Nguyen NQ, Fraser RJ, Richards DB, Hacquoil KE, Vasist Johnson LS, Barton ME, Dukes GE. The effect of camicinal (GSK962040), a motilin agonist, on gastric emptying and glucose absorption in feed-intolerant critically ill patients: a randomized, blinded, placebo-controlled, clinical trial. Crit Care. 2016 Aug 1;20(1):232. doi: 10.1186/s13054-016-1420-4. PubMed PMID: 27476581; PubMed Central PMCID: PMC4967996.

6: Camilleri M. Novel Diet, Drugs, and Gastric Interventions for Gastroparesis. Clin Gastroenterol Hepatol. 2016 Aug;14(8):1072-80. doi: 10.1016/j.cgh.2015.12.033. Epub 2016 Jan 4. Review. PubMed PMID: 26762845; PubMed Central PMCID: PMC4931993.

7: Hellström PM, Tack J, Johnson LV, Hacquoil K, Barton ME, Richards DB, Alpers DH, Sanger GJ, Dukes GE. The pharmacodynamics, safety and pharmacokinetics of single doses of the motilin agonist, camicinal, in type 1 diabetes mellitus with slow gastric emptying. Br J Pharmacol. 2016 Jun;173(11):1768-77. doi: 10.1111/bph.13475. Epub 2016 Apr 13. PubMed PMID: 26924243; PubMed Central PMCID: PMC4867742.

8: Sanger GJ. Ghrelin and motilin receptor agonists: time to introduce bias into drug design. Neurogastroenterol Motil. 2014 Feb;26(2):149-55. doi: 10.1111/nmo.12300. Review. PubMed PMID: 24438586.

9: Sanger GJ, Furness JB. Ghrelin and motilin receptors as drug targets for gastrointestinal disorders. Nat Rev Gastroenterol Hepatol. 2016 Jan;13(1):38-48. doi: 10.1038/nrgastro.2015.163. Epub 2015 Sep 22. Review. PubMed PMID: 26392067.

10: Broad J, Góralczyk A, Mannur K, Dukes GE, Sanger GJ. Drugs acting at 5-HT4 , D2 , motilin, and ghrelin receptors differ markedly in how they affect neuromuscular functions in human isolated stomach. Neurogastroenterol Motil. 2014 Jun;26(6):851-61. doi: 10.1111/nmo.12338. Epub 2014 Apr 20. PubMed PMID: 24750304.